Cresco Labs (CL) Aktievy
Cresco Labs Inc. odlar, tillverkar och säljer cannabisprodukter för detaljhandel och medicinsk användning i USA. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 5/6 |
| Framtida tillväxt | 0/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 3/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
CL Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Cresco Labs Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | CA$1.49 |
| 52 veckors högsta | CA$3.12 |
| 52 veckors lägsta | CA$0.60 |
| Beta | 1.65 |
| 1 månads förändring | 11.19% |
| 3 månaders förändring | 2.76% |
| 1 års förändring | 21.14% |
| 3 års förändring | -33.48% |
| 5 års förändring | -90.59% |
| Förändring sedan börsintroduktionen | -77.25% |
Senaste nyheter och uppdateringar
CL: Discount-Adjusted Outlook Will Support Future Upside From Speculative Buy Rating
Analysts have trimmed their CA$ price target on Cresco Labs from CA$2.50 to CA$2.25, reflecting updated expectations for the discount rate, profit margin and future P/E assumptions. Analyst Commentary The revised CA$2.25 price target signals that analysts are updating their view of Cresco Labs as they refresh discount rate, margin and P/E assumptions, rather than completely changing their stance on the business.CL: Revised Outlook Will Support Future Upside From Speculative Buy Rating
Analysts have reduced their price target on Cresco Labs to CA$2.25 from CA$2.50, citing updated assumptions regarding fair value, discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts have adjusted their view on Cresco Labs by trimming the price target to CA$2.25 from CA$2.50 while maintaining a Speculative Buy stance, which reflects both perceived upside potential and meaningful execution risk.
CL: Lower P/E Assumptions Will Support A More Upside-Skewed Outlook
Analysts now see Cresco Labs' fair value as aligning with a trimmed CA$2.25 price target, down from CA$2.50. This reflects updated views on growth, margins and a lower future P/E assumption.Recent updates
CL: Discount-Adjusted Outlook Will Support Future Upside From Speculative Buy Rating
Analysts have trimmed their CA$ price target on Cresco Labs from CA$2.50 to CA$2.25, reflecting updated expectations for the discount rate, profit margin and future P/E assumptions. Analyst Commentary The revised CA$2.25 price target signals that analysts are updating their view of Cresco Labs as they refresh discount rate, margin and P/E assumptions, rather than completely changing their stance on the business.CL: Revised Outlook Will Support Future Upside From Speculative Buy Rating
Analysts have reduced their price target on Cresco Labs to CA$2.25 from CA$2.50, citing updated assumptions regarding fair value, discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts have adjusted their view on Cresco Labs by trimming the price target to CA$2.25 from CA$2.50 while maintaining a Speculative Buy stance, which reflects both perceived upside potential and meaningful execution risk.CL: Lower P/E Assumptions Will Support A More Upside-Skewed Outlook
Analysts now see Cresco Labs' fair value as aligning with a trimmed CA$2.25 price target, down from CA$2.50. This reflects updated views on growth, margins and a lower future P/E assumption.CL: Higher Future P/E Assumptions Will Shape A More Upside-Skewed Outlook
Analysts have lowered their price target on Cresco Labs to CA$2.25 from CA$2.50, reflecting updated views on revenue growth, profit margins, and a much higher assumed future P/E multiple. Analyst Commentary Bearish analysts are signaling a more cautious stance on Cresco Labs by trimming their price target to CA$2.25 from CA$2.50, even while still seeing speculative upside potential.CL: Expanded Retail Footprint And Flexible Equity Program Will Support A More Optimistic Outlook
Analysts have revised their price target on Cresco Labs to CA$16.91 from CA$18.36, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. What's in the News Cresco Labs filed a follow on equity offering for up to CA$140 million of Subordinate Voting Shares through an at the market program, giving the company flexibility to raise capital over time (Key Developments).Cresco Labs Inc. (CSE:CL) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless
Feb 12
CL: Expanded Retail And EU Entry Will Support A More Optimistic Outlook
Analysts have lifted their price target on Cresco Labs to US$1.94 from US$1.51, citing revised assumptions around revenue growth, profit margins, discount rate, and a lower future P/E multiple as key drivers of the change. What's in the News Cresco Labs filed a follow on equity offering of up to C$140 million in subordinate voting shares through an at the market program, adding flexibility to raise capital as needed (Key Developments).CL: New German Entry Will Support Future Upside
Analysts have nudged their price target for Cresco Labs higher, now implying fair value of about $2.40 per share versus roughly $2.36 previously. The change reflects updated views on revenue growth, profit margins and future P/E assumptions.CL: German Entry And Higher Margins Will Support Future Upside
Analysts have raised their price target for Cresco Labs from US$2.30 to about US$2.36, reflecting updated views on the company’s profit margin outlook and a lower assumed future P/E multiple. What's in the News Cresco Labs launched Cresco branded flower in Germany, marking its first commercial entry into the European Union and extending its growth plans beyond the U.S. cannabis market (Key Developments).CL: Expanded Retail And European Entry Will Support Stronger Profitability
Analysts have modestly raised their price target on Cresco Labs to reflect an updated fair value estimate of approximately 2.30 dollars, up from about 2.16 dollars previously, citing expectations for stronger revenue growth, improved profit margins, a slightly lower discount rate, and a more reasonable future earnings multiple. What's in the News Entered the European Union with the launch of Cresco branded flower in Germany, using the market as a testbed for broader international expansion beyond U.S. cannabis (Key Developments).Cresco Labs Inc. (CSE:CL) Not Doing Enough For Some Investors As Its Shares Slump 37%
Nov 26Here's Why Cresco Labs (CSE:CL) Is Weighed Down By Its Debt Load
Nov 08Optimistic Investors Push Cresco Labs Inc. (CSE:CL) Shares Up 35% But Growth Is Lacking
Oct 12Is Cresco Labs Inc. (CSE:CL) Trading At A 49% Discount?
Sep 06Optimistic Investors Push Cresco Labs Inc. (CSE:CL) Shares Up 27% But Growth Is Lacking
Jul 31Cresco Labs (CSE:CL) Takes On Some Risk With Its Use Of Debt
Jul 23Cresco Labs Inc.'s (CSE:CL) 30% Share Price Plunge Could Signal Some Risk
Jun 15Cresco Labs Inc.'s (CSE:CL) Shares Climb 31% But Its Business Is Yet to Catch Up
May 01
Expanding Production In Illinois, Pennsylvania And Kentucky Will Meet Demand
Expansion in Illinois and Pennsylvania and entry into Kentucky's market aim to boost revenue growth and market share.Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 27%
Mar 07Is Cresco Labs (CSE:CL) A Risky Investment?
Jan 31Cresco Labs Inc. (CSE:CL) May Have Run Too Fast Too Soon With Recent 28% Price Plummet
Dec 14Getting In Cheap On Cresco Labs Inc. (CSE:CL) Is Unlikely
Oct 24Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
Aug 11Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%?
Jul 17Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden
Jun 19Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Jun 19Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41
Mar 16Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%
Mar 03Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt
Jan 26Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL)
Jan 04Aktieägarnas avkastning
| CL | CA Pharmaceuticals | CA Marknad | |
|---|---|---|---|
| 7D | 8.8% | 3.9% | 0.1% |
| 1Y | 21.1% | 44.9% | 35.1% |
Avkastning vs industri: CL presterade sämre än Canadian Pharmaceuticals branschen som gav 44.9 % under det senaste året.
Avkastning vs Marknaden: CL presterade sämre än Canadian marknaden som gav 35.1 % under det senaste året.
Prisvolatilitet
| CL volatility | |
|---|---|
| CL Average Weekly Movement | 17.7% |
| Pharmaceuticals Industry Average Movement | 12.1% |
| Market Average Movement | 10.6% |
| 10% most volatile stocks in CA Market | 18.1% |
| 10% least volatile stocks in CA Market | 3.9% |
Stabil aktiekurs: CL s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för Canadian.
Volatilitet över tid: CL s veckovolatilitet ( 18% ) har varit stabil under det senaste året, men är fortfarande högre än 75 % av Canadian aktier.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| n/a | 2,900 | Charlie Bachtell | www.crescolabs.com |
Cresco Labs Inc. odlar, tillverkar och säljer cannabisprodukter för detaljhandel och medicinsk användning i USA. Det tillhandahåller cannabis i blommor, vape-pennor, levande hartser, engångspennor och extrakt under varumärket Cresco; vape-vagnar, vape-pennor, blommor, popcorn, shake, pre-rolls, shorties och koncentrat under varumärket High Supply; vapes och gummier under varumärket Good News; vapes och ätbara produkter under varumärket Wonder Wellness Co.; och tinkturer, kapslar, salvor och sublinguala oljor under varumärket Remedi. Företaget erbjuder cannabisblommor under varumärket FloraCal; och cannabisoljor och olika bett finns tillgängliga på flera styrka nivåer under varumärket Mindy's Edibles, samt licenser varumärket Kiva.
Cresco Labs Inc. Sammanfattning av grunderna
| CL grundläggande statistik | |
|---|---|
| Börsvärde | CA$678.16m |
| Vinst(TTM) | -CA$184.05m |
| Intäkter(TTM) | CA$891.44m |
Är CL övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| CL resultaträkning (TTM) | |
|---|---|
| Intäkter | US$655.85m |
| Kostnad för intäkter | US$331.28m |
| Bruttovinst | US$324.57m |
| Övriga kostnader | US$459.98m |
| Intäkter | -US$135.41m |
Senast redovisade vinst
Dec 31, 2025
Nästa vinstdatum
May 08, 2026
| Vinst per aktie (EPS) | -0.37 |
| Bruttomarginal | 49.49% |
| Nettovinstmarginal | -20.65% |
| Skuld/egenkapitalförhållande | 132.1% |
Hur har CL utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/03 16:25 |
| Aktiekurs vid dagens slut | 2026/05/01 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Cresco Labs Inc. bevakas av 13 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Russell Stanley | Beacon Securities Limited |